TRPV1 protein may cause symptoms similar to asthma attack in children with respiratory syncytial virus, does not respond to existing asthma medication.
Researchers in the United States have identified a protein that may be causing asthma-like coughing and wheezing in children, without those children having any kind of allergy to trigger the disease.
The World Health Organization estimates around 235 million people suffer from asthma worldwide, causing more than 380,000 deaths each year, and it is the most common non-communicable disease among children. The disease is often linked to allergies, such as a reaction to dust, pollen, smoke or pollution.
In a new study published in the Journal of Allergy and Clinical Immunology, researchers at the Cleveland Clinic found that the protein TRPV1 – transient receptor potential vanilloid 1, a protein that plays a role in airway disease through mucus production, cough reflex stimulation and airway narrowing – may also be responsible for asthma-like symptoms in children even in the absence of allergies.
“Many people believe that asthma is essentially an allergic process and for years we’ve looked at alternative pathways that can make non-allergic children have inflammation in their airways and start coughing,” said Giovanni Piedimonte, M.D., pediatric pulmonologist at the Cleveland Clinic and lead author of the study.
“TRPV1 plays a critical role in the mechanism of cough, though it is not linked to immune or allergic mechanisms. Many young children cough and wheeze when they get infected by respiratory syncytial virus (RSV) – similar to an asthma attack – but they do not respond to typical drugs we give for adult asthmatics, and this study might explain why.”
Using bronchial epithelial cells from the lungs of deceased donors, Cleveland Clinic researchers compared TRPV1 expression in children and adults, both with and without asthma; the measurement was then repeated after infecting the cells with RSV. They found that RSV infection greatly increased TRPV1 activation in children, but not adults.
RSV infection of airway epithelium in children – but not adults – changes the function of calcium channels involved in bronchoconstriction, mucus production, and cough, which may contribute to viral bronchiolitis and asthma. The expression of TRPV1 increases in those diagnosed with asthma and is further increased by viral infections.
By understanding better the mechanism by which these channels are regulated, the channels can then be targeted with a new generation of molecules and new drugs to control cough and wheezing in childhood.
“Cough does not receive the attention it deserves,” adds Piedimonte. “One thing that characterizes humans is the ability to cough. Unfortunately, we currently do not have good therapies for cough, and most of the available cough medications contain opioids. According to the American Academy of Pediatrics, cough medicines should not be prescribed or used for children under six years of age. These products can have potentially serious side effects and they do not treat the problem – they just numb the system. Moreover, an FDA advisory committee recently declared ‘nearly unanimously that the risks of using certain opioids in children’s cough medications outweighs the benefits.’ If one day we can understand better the mechanism of cough, we can generate medications that control it in a physiological way.”
Currently, there are no approved drugs available that inhibit the TRPV1 channel – which produces cough. Future pharmacological advances pertaining to TRPV1 may also help reduce the impact of RSV infections in both asthmatic and non-asthmatic children.
Source: Cleveland Clinic